A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

BACKGROUND: AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs). It shows encouraging anti-cancer activity against multiple cell lines and in tumour xenografts. This phase I study was conducted to evaluate the safety and tolerability of AT7519 given as 1-h intravenous i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, E X, Hotte, S, Hirte, H, Siu, L L, Lyons, J, Squires, M, Lovell, S, Turner, S, McIntosh, L, Seymour, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264455/
https://www.ncbi.nlm.nih.gov/pubmed/25393368
http://dx.doi.org/10.1038/bjc.2014.565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264455/
https://www.ncbi.nlm.nih.gov/pubmed/25393368
http://dx.doi.org/10.1038/bjc.2014.565

Ejemplares similares